Managing Joint Pain from Aromatase Inhibitors in Breast Cancer Treatment
Author Information
Author(s): Carter Thorne
Primary Institution: The Arthritis Program, Southlake Regional Health Centre
Hypothesis
How can we effectively manage arthralgia associated with aromatase inhibitor therapy in postmenopausal women with breast cancer?
Conclusion
Arthralgia and myalgia are common side effects of aromatase inhibitor therapy, but they can be managed with lifestyle changes and medications.
Supporting Evidence
- 25% of postmenopausal women on aromatase inhibitors report arthralgia.
- The ma.17 trial showed a 25% incidence of arthralgia in patients on letrozole compared to 21% on placebo.
- The atac trial found a higher incidence of arthralgia in the anastrozole group compared to tamoxifen.
Takeaway
Some women taking medicine for breast cancer might have joint pain, but there are ways to help them feel better, like exercise and medicine.
Methodology
The review discusses various trials and studies comparing the effects of aromatase inhibitors and tamoxifen on joint symptoms in postmenopausal women.
Potential Biases
Potential bias may arise from the reliance on self-reported symptoms and the variability in patient responses to treatment.
Limitations
The review does not provide extensive data on long-term effects or the effectiveness of all potential interventions.
Participant Demographics
Postmenopausal women with hormone receptor-positive breast cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website